DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY - CBC
COMPLETE CARE ACTIVE WOMEN
BLOOD COUNTS, EDTA WHOLE BLOOD
HEMOGLOBIN (HB) 13.2 12.0 - 15.0 g/dL
METHOD : SPECTROPHOTOMETRY
RED BLOOD CELL (RBC) COUNT 4.33 3.8 - 4.8 mil/µL
METHOD : ELECTRICAL IMPEDANCE
WHITE BLOOD CELL (WBC) COUNT 9.77 4 - 10 thou/µL
METHOD : IMPEDANCE
PLATELET COUNT 247 150 - 410 thou/µL
METHOD : IMPEDANCE

RBC AND PLATELET INDICES

HEMATOCRIT (PCV) 40.0 36.0 - 46.0 %
METHOD : CALCULATED
MEAN CORPUSCULAR VOLUME (MCV) 92.3 83.0 - 101.0 fL
METHOD : DERIVED FROM IMPEDANCE MEASURE
MEAN CORPUSCULAR HEMOGLOBIN (MCH) 30.5 27.0 - 32.0 pg
METHOD : CALCULATED PARAMETER
MEAN CORPUSCULAR HEMOGLOBIN 33.0 31.5 - 34.5 g/dL
CONCENTRATION(MCHC)
METHOD : CALCULATED PARAMETER
RED CELL DISTRIBUTION WIDTH (RDW) 17.1 High 11.6 - 14.0 %
METHOD : DERIVED FROM IMPEDANCE MEASURE
MENTZER INDEX 21.3
METHOD : CALCULATED
MEAN PLATELET VOLUME (MPV) 11.0 High 6.8 - 10.9 fL
METHOD : DERIVED FROM IMPEDANCE MEASURE

WBC DIFFERENTIAL COUNT

NEUTROPHILS 56 40 - 80 %
METHOD : DHSS FLOWCYTOMETRY
LYMPHOCYTES 37 20 - 40 %
METHOD : DHSS FLOWCYTOMETRY

Page 1 Of 19

Dr. Anurag Bansal Dr. Arpita Roy, MD,MCI-18052

LAB DIRECTOR Section Head - Hematology &
Head QA

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

MONOCYTES 4 2.0 - 10.0 %

METHOD : DHSS FLOWCYTOMETRY
EOSINOPHILS 3 1-6 %
METHOD : DHSS FLOWCYTOMETRY
BASOPHILS 0 0-2 %
METHOD : IMPEDANCE
ABSOLUTE NEUTROPHIL COUNT 5.43 2-7 thou/µL
METHOD : CALCULATED
ABSOLUTE LYMPHOCYTE COUNT 3.65 High 1.0 - 3.0 thou/µL
METHOD : CALCULATED
ABSOLUTE MONOCYTE COUNT 0.42 0.20 - 1.00 thou/µL
METHOD : CALCULATED
ABSOLUTE EOSINOPHIL COUNT 0.24 0.02 - 0.50 thou/µL
METHOD : CALCULATED
ABSOLUTE BASOPHIL COUNT 0.00 0.0 - 0.10 thou/µL
METHOD : CALCULATED
NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.5
METHOD : CALCULATED

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)
from Beta thalassaemia trait
(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for
diagnosing a case of beta thalassaemia trait.
WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive
patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <
3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.

Page 2 Of 19

Dr. Anurag Bansal Dr. Arpita Roy, MD,MCI-18052

LAB DIRECTOR Section Head - Hematology &
Head QA

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY
COMPLETE CARE ACTIVE WOMEN
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE
BLOOD
HBA1C 6.3 High Non-diabetic: < 5.7 %
Pre-diabetics: 5.7 - 6.4
Diabetics: > or = 6.5
ADA Target: 7.0
Action suggested: > 8.0
METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
ESTIMATED AVERAGE GLUCOSE(EAG) 134.1 High < 116 mg/dL
METHOD : CALCULATED PARAMETER

Interpretation(s)
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for
well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic
anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates
addiction are reported to interfere with some assay methods,falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is
recommended for detecting a hemoglobinopathy

Page 3 Of 19

Dr. Anurag Bansal Dr. Arpita Roy, MD,MCI-18052

LAB DIRECTOR Section Head - Hematology &
Head QA

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

BIOCHEMISTRY
COMPLETE CARE ACTIVE WOMEN
GLUCOSE FASTING,FLUORIDE PLASMA
FBS (FASTING BLOOD SUGAR) 106 High mg/dL
(Normal <100,Impaired fasting
glucose:100 to 125,Diabetes
mellitus:>=126(on more than
1 occasion)(ADA guidelines
2024)
METHOD : SPECTROPHOTOMETRY HEXOKINASE

KIDNEY FUNCTION TEST, SERUM

BLOOD UREA NITROGEN 9.0 6 - 20 mg/dL
METHOD : SPECTROPHOTOMETRY, KINETIC TEST WITH UREASE AND GLUTAMATE DEHYDROGENASE
CREATININE 0.96 High 0.5 - 0.9 mg/dL
METHOD : SPECTROPHOTOMETRIC, JAFFE'S KINETICS
BUN/CREAT RATIO 9.38 8.0 - 15.0
METHOD : CALCULATED PARAMETER
URIC ACID 5.3 2.4 - 5.7 mg/dL
METHOD : SPECTROPHOTOMETRY, URICASE
TOTAL PROTEIN 7.2 6.0 - 8.0 g/dL
METHOD : SPECTROPHOTOMETRY, BIURET
ALBUMIN 4.2 3.97 - 4.94 g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING
GLOBULIN 3.0 2.0 - 3.5 g/dL
METHOD : CALCULATED PARAMETER
CALCIUM 9.0 8.6 - 10.0 mg/dL
METHOD : SPECTROPHOTOMETRY, NM - BAPTA
SODIUM, SERUM 141 135 - 145 mmol/L
METHOD : ISE INDIRECT
POTASSIUM, SERUM 3.8 3.5 - 5.3 mmol/L
METHOD : ISE INDIRECT
CHLORIDE, SERUM 100 97 - 110 mmol/L
METHOD : ISE INDIRECT

Page 4 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL 0.6 Upto 1.2 mg/dL
METHOD : COLORIMETRIC DIAZO METHOD
BILIRUBIN, DIRECT 0.3 < 0.30 mg/dL
METHOD : COLORIMETRIC DIAZO METHOD
BILIRUBIN, INDIRECT 0.30 0.1 - 1.0 mg/dL
METHOD : CALCULATED PARAMETER
TOTAL PROTEIN 7.2 6.0 - 8.0 g/dL
METHOD : SPECTROPHOTOMETRY, BIURET
ALBUMIN 4.2 3.97 - 4.94 g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING
GLOBULIN 3.0 2.0 - 3.5 g/dL
METHOD : CALCULATED PARAMETER
ALBUMIN/GLOBULIN RATIO 1.4 1.0 - 2.1 RATIO
METHOD : CALCULATED PARAMETER
ASPARTATE AMINOTRANSFERASE(AST/SGOT) 23 < OR = 35 U/L
METHOD : SPECTROPHOTOMETRY, WITH PYRIDOXAL PHOSPHATE ACTIVATION-IFCC
ALANINE AMINOTRANSFERASE (ALT/SGPT) 23 < OR = 35 U/L
METHOD : SPECTROPHOTOMETRY, WITH PYRIDOXAL PHOSPHATE ACTIVATION-IFCC
ALKALINE PHOSPHATASE 69 35 - 104 U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC
GAMMA GLUTAMYL TRANSFERASE (GGT) 35 0 - 40 U/L
METHOD : ENZYMATIC COLORIMETRIC ASSAY STANDARDIZED AGAINST IFCC / SZASZ
LACTATE DEHYDROGENASE 233 High 125 - 220 U/L
METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC

PHOSPHORUS, SERUM
PHOSPHORUS 4.5 2.5 - 4.5 mg/dL
METHOD : SPECTROPHOTOMETRY, MOLYBDATE UV METHOD

MAGNESIUM, SERUM
MAGNESIUM, SERUM 2.6 1.6 - 2.6 mg/dL
METHOD : COLORIMETRIC ENDPOINT METHOD

Page 5 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

Page 6 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

COMPLETE CARE ACTIVE WOMEN

LIPID PROFILE WITH CALCULATED LDL, SERUM
CHOLESTEROL, TOTAL 168 Desirable : < 200 mg/dL
Borderline : 200 - 239
High : > / = 240
METHOD : ENZYMATIC COLORIMETRIC ASSAY
TRIGLYCERIDES 141 Normal: < 150 mg/dL
Borderline high: 150 - 199
High: 200 - 499
Very High: >/= 500
METHOD : ENZYMATIC COLORIMETRIC ASSAY
HDL CHOLESTEROL 44 At Risk: < 40 mg/dL
Desirable: > or = 60
METHOD : HOMOGENEOUS ENZYMATIC COLORIMETRIC ASSAY
CHOLESTEROL LDL 96 Adult levels: mg/dL
Optimal < 100
Near optimal/above optimal:
100-129
Borderline high : 130-159
High : 160-189
Very high : = 190
METHOD : HOMOGENEOUS ENZYMATIC COLORIMETRIC ASSAY
NON HDL CHOLESTEROL 124 Desirable : < 130 mg/dL
Above Desirable : 130 -159
Borderline High : 160 - 189
High : 190 - 219
Very high : > / = 220
METHOD : CALCULATED PARAMETER
VERY LOW DENSITY LIPOPROTEIN 28.2 < OR = 30.0 mg/dL
METHOD : CALCULATED PARAMETER
CHOL/HDL RATIO 3.8 Low Risk : 3.3 - 4.4
Average Risk : 4.5 - 7.0
Moderate Risk : 7.1 - 11.0
High Risk : > 11.0
METHOD : CALCULATED PARAMETER
LDL/HDL RATIO 2.2 0.5 - 3.0 Desirable/Low Risk
3.1 - 6.0 Borderline/Moderate
Risk
>6.0 High Risk
METHOD : CALCULATED PARAMETER

Page 7 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

Interpretation(s)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION
Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the
urine.
Increased in:Diabetes mellitus, Cushing’ s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.
Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,
malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

Page 8 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within
individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.
High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic
index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc.
LIVER FUNCTION PROFILE, SERUM-
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give
yellow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg,
obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated
(indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when
there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin
may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that
attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured
clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic
anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT
is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of
hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic
hepatitis,obstruction of bile ducts,cirrhosis.
ALP is a protein found in almost all body tissues.Tissues with higher amounts of ALP include the liver,bile ducts and bone.Elevated ALP levels are seen in Biliary obstruction,
Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen
in Hypophosphatasia,Malnutrition,Protein deficiency,Wilsons disease.
GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas.It is also found in other tissues including intestine,spleen,heart, brain
and seminal vesicles.The highest concentration is in the kidney,but the liver is considered the source of normal enzyme activity.Serum GGT has been widely used as an
index of liver dysfunction.Elevated serum GGT activity can be found in diseases of the liver,biliary system and pancreas.Conditions that increase serum GGT are obstructive
liver disease,high alcohol consumption and use of enzyme-inducing drugs etc.
Total Protein also known as total protein,is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and
globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms
disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic
syndrome,Protein-losing enteropathy etc.
Albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels
(hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular
permeability or decreased lymphatic clearance,malnutrition and wasting etc
MAGNESIUM, SERUM-Description- Magnesium is primariliy an intracellular ion associated with GI absorption and renal excretion. Second most abundant ion in bone.It
functions as co-factor in numerous enzymes e.g. ATPase . 65-70% of Mg is in ionized state and nearly 35% is protein bound.

Interpretation-
Increased in- Dehydration, Tissue trauma, Renal failure, Hypothyroidism, excessive intake of antacid.
Decrease in- Chronic diarrhea, Enteric fistula, Starvation, Chronic alcoholism, Total parenteral Nutrition, Diuretics.

Note- Hypomagnesemia is associated with weakness, tetany, disorientation and somnolence

Limitation-
• Hemolysis yields elevated levels of Mg being an intracellular ion.
• Serum magnesium levels may remain normal even when total body stores of magnesium are depleted upto 20%

Page 9 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

NEPHELOMETRY
COMPLETE CARE ACTIVE WOMEN
HIGH SENSITIVITY C-REACTIVE PROTEIN, SERUM
HIGH SENSITIVITY CRP 9.9 High Low risk for CAD: < 1.00 mg/L
Average risk for caD: 1.00 -
3.00
High risk for CAD: > 3.00
METHOD : PARTICLE ENHANCED IMMUNOTURBIDIMETRIC ASSAY

Interpretation(s)
HIGH SENSITIVITY C-REACTIVE PROTEIN, SERUM-High sensitivity CRP measurements may be used as an independent risk marker for the identification of individuals at risk
for future cardiovascular disease. Measurement of hs- CRP, when used in conjunction with traditional clinical laboratory evaluation of acute coronary syndromes, may be
useful as an independent marker of prognosis for recurrent events, in patients with stable coronary disease or acute coronary syndromes.
When using this assay for risk assessment, patients with persistently unexplained, marked elevation of hs- CRP (> 10mg/l) after repeated testing should be evaluated for
non cardiovascular etiologies. In Rheumatic and other inflammatory diseases, value of CRP less than 10 mg/l is considered satisfactory. More than 10 mg/l suggests disease
activity. Patients with evidence of active infection, systemic inflammatory processes or trauma should not be tested for cardiovascular disease risk assessment until these
conditions have abated
Hs- CRP levels should not be substituted for assessment of traditional cardiovascular risk factors.
Turbidity and particles in the sample may interfere with the determination. Patient samples which contain heterophilic antibodies could react in immunoassays to give a
falsely elevated or depressed result.
Results of this test should always be interpreted in conjunction with the patient’s medical history, clinical presentation and other findings.

References:

1. Teitz textbook of clinical chemistry and Molecular diagnostics, edited by Carl A Burtis, Edward R. Ashrwood, David E Bruns, 4th edition, Elseiver publication, 2006,962-966
2. Parson TA, Mensah GA, et al. Marker of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation 2003,107,499-511
3. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice: Jacyln Anderson, Liron Caplin et al, Wiley
online, 2012.

Page 10 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

ENDOCRINOLOGY
COMPLETE CARE ACTIVE WOMEN
THYROID PANEL II (FT3,FT4,TSH) SERUM
FREE TRIIODOTHYRONINE (FT3) 2.77 2 - 4.4 pg/mL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY
FREE THYROXINE (FT4) 1.17 0.93 - 1.7 ng/dL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY
TSH (ULTRASENSITIVE) 3.730 Non Pregnant Women µIU/mL
0.27 - 4.20
Pregnant Women (As per
American Thyroid Association)
1st Trimester 0.100 - 2.500
2nd Trimester 0.200 - 3.000
3rd Trimester 0.300 - 3.000
METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY

Interpretation(s)

Page 11 Of 19

Dr. Anurag Bansal Dr.Rashmi Rasi Datta-MD,FIMSA

LAB DIRECTOR DMC-64289
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

Page 12 Of 19

Dr. Anurag Bansal Dr.Rashmi Rasi Datta-MD,FIMSA

LAB DIRECTOR DMC-64289
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - ANEMIA

COMPLETE CARE ACTIVE WOMEN
SERUM IRON AND TIBC STUDIES
IRON 73 37 - 145 µg/dL
METHOD : SPECTROPHOTOMETRY,FERROZINE
TOTAL IRON BINDING CAPACITY 306 250 - 400 µg/dL
METHOD : CALCULATED PARAMETER
% SATURATION 24.0 15 - 50 %
METHOD : CALCULATED PARAMETER

Interpretation(s)
SERUM IRON AND TIBC STUDIES-Total iron binding capacity (TIBC) measures the blood’s capacity to bind iron with transferrin and thus is an indirect way of assessing
transferrin level.
Taken together with serum iron and percent transferrin saturation this test is performed when they is a concern about anemia, iron deficiency or iron deficiency anemia.
However, because the liver produces transferrin, alterations in liver function (such as cirrhosis, hepatitis, or liver failure) must be considered when performing this test.
Increased in:
- iron deficiency
- acute and chronic blood loss
- acute liver damage
- progesterone birth control pills
Decreased in:
- hemochromatosis
- cirrhosis of the liver
- thalassemia
- anemias of infection and chronic diseases
- nephrosis
- hyperthyroidism
The percent Transferrin saturation = Serum Iron/TIBC x 100
Unsaturated Binding Capacity (UIBC)=TIBC - Serum Iron.
Limitations: Estrogens and oral contraceptives increase TIBC and Asparaginase, chloramphenicol, corticotropin, cortisone and testosterone decrease the TIBC level.

Reference:
1.Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006, 563,
1314-1315.
2. Wallach’s Interpretation of Diagnostic tests, 9th Edition, Ed Mary A Williamson and L Michael Snyder. Pub Lippincott Williams and Wilkins, 2011, 234-235.

Page 13 Of 19

Dr. Anurag Bansal Dr.Rashmi Rasi Datta-MD,FIMSA

LAB DIRECTOR DMC-64289
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

COMPLETE CARE ACTIVE WOMEN
PHYSICAL EXAMINATION, URINE
COLOR PALE YELLOW
METHOD : MANUAL
APPEARANCE TURBID
METHOD : MANUAL

Comments

NOTE : MICROSCOPIC EXAMINATION OF URINE IS PERFORMED ON CENTRIFUGED URINARY SEDIMENT.

IN NORMAL URINE SAMPLES CAST AND CRYSTALS ARE NOT DETECTED.
CHEMICAL EXAMINATION, URINE
PH 6.5 4.5 - 7.5
METHOD : DOUBLE INDICATOR PRINCIPLE
SPECIFIC GRAVITY 1.015 1.005 - 1.030
METHOD : IONIC CONCENTRATION METHOD/DIPSTICK
PROTEIN TRACE NOT DETECTED
METHOD : PROTEIN-ERROR-OF INDICATORS PRINCIPLE
GLUCOSE NOT DETECTED NEGATIVE
METHOD : PEROXIDASE / MANUAL
KETONES NOT DETECTED NOT DETECTED
METHOD : NITROPRUSSIDE REACTION / MANUAL
BLOOD DETECTED (+) NOT DETECTED
METHOD : DISOPROPLBENZENE / MANUAL
BILIRUBIN NOT DETECTED NOT DETECTED
METHOD : DICHLOROANILINE / MANUAL
UROBILINOGEN Nor NORMAL
METHOD : DIETHYLAMINOBENZ ALDEHYDE / MANUAL
NITRITE NOT DETECTED NOT DETECTED
METHOD : DIAZONIUM COMPOUND METHOD
LEUKOCYTE ESTERASE DETECTED (+++) NOT DETECTED
METHOD : ESTERASES/DIPSTICK

Page 14 Of 19

Dr. Anurag Bansal

LAB DIRECTOR

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS 3-5 NOT DETECTED /HPF
METHOD : MICROSCOPY
PUS CELL (WBC’S) 30-40 0-5 /HPF
METHOD : MICROSCOPY
EPITHELIAL CELLS 5-7 0-5 /HPF
METHOD : MICROSCOPY
CASTS NOT DETECTED
METHOD : MICROSCOPY
CRYSTALS NOT DETECTED
METHOD : MICROSCOPY
BACTERIA DETECTED (FEW) NOT DETECTED
METHOD : MICROSCOPY
YEAST NOT DETECTED NOT DETECTED
METHOD : MICROSCOPY

Interpretation(s)

Page 15 Of 19

Dr. Anurag Bansal

LAB DIRECTOR

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

Page 16 Of 19

Dr. Anurag Bansal

LAB DIRECTOR

View Details View Report

PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - TUMOR MARKER

COMPLETE CARE ACTIVE WOMEN
CA 125 (OVARIAN CANCER MONITOR), SERUM
CA 125 9.5 < 35 U/mL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY

Interpretation(s)
CA 125 (OVARIAN CANCER MONITOR), SERUM-CA 125 is a surface antigen, identified as a 200-1000 kDa mucin-like glycoprotein associated with non-mucinous epithelial
ovarian malignancy. CA 125 is a useful tumor marker for evaluating therapy and monitoring disease status in patients under treatment for ovarian cancer. Measured serially
the levels of CA 125 correspond with disease progression or regression. The rate of change in CA 125 is also highly prognostic. As a diagnostic tool however, the level of CA
125 alone is not sufficient to determine the presence or extent of disease. Levels of CA 125 should not be interpreted as absolute evidence of the presence or the absence of
malignant diseases. Before treatment, patients with confirmed ovarian carcinoma frequently have levels of CA 125 within the range observed in healthy individuals.
Preoperative levels of CA 125 in patients with malignant pelvic masses provide no information regarding the histological grade or diameter of the tumor mass.

Elevated levels of CA 125 can be observed in patients with nonmalignant diseases. Patients with certain benign conditions, such as hepatic cirrhosis, acute pancreatitis,
endometriosis, pelvic inflammatory disease, menstruation and first trimester pregnancy show elevated levels of CA 125. Elevated levels are also found in 1 to 2% of healthy
donors.

Measurements of CA 125 should always be used in conjunction with other diagnostic procedures, including information from the patients clinical evaluation. The
concentration of CA 125 in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods, calibration, and reagent
specificity. Values obtained with different assay methods cannot be used interchangeably. Heterophilic antibodies in human serum can react with reagent immunoglobulins,
interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous values may be
observed

Page 17 Of 19

Dr.Rashmi Rasi Datta-MD,FIMSA Dr. Anurag Bansal

DMC-64289 LAB DIRECTOR
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - VITAMIN

COMPLETE CARE ACTIVE WOMEN
25 - HYDROXYVITAMIN D(VITAMIN D TOTAL), SERUM
25 - HYDROXYVITAMIN D 19.0 Low Deficiency: < 20.0 ng/mL
Insufficiency: 20.0 - < 30.0
Sufficiency: 30.0 -100.0
Toxicity > 100.0
METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY

VITAMIN B12(CYANOCOBALAMINE), SERUM

VITAMIN B12 570 197 - 771 pg/mL
METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY

Interpretation(s)
25 - HYDROXYVITAMIN D(VITAMIN D TOTAL), SERUM-Test description
Vitamin D has anti-inflammatory and immune-modulating properties and it works towards the bones, teeth, intestines, immune system, pancreas, muscles and brain. It
helps to maintain normal calcium and phosphate levels.Vitamin D is a fat-soluble vitamin. Also called as “Sunshine Vitamin”.Two main forms as Cholecalciferol (vitamin D3)
which is synthesized in skin from 7-dehydrocholesterol in response to sunlight (Type B UV) exposure & Ergocalciferol (vitamin D2) present mainly in dietary sources.
Vit D25(OH)D deficiency is seen due to poor or inadequate sunlight exposure, Nutritional or dietary deficiency or fat malabsorption, Severe Hepatocellular disease,
Secondary hyperparathyroidism, Hypocalcemia tetany which can cause involuntary contraction of muscles, leading to cramps and spasms, Rickets in children, Osteomalacia
in adults- due to vitamin D deficiency mainly, Older adults- osteoporosis. (Increased risk of bone fractures)due to long-term effect of calcium and/or vitamin D deficiency,
Other conditions that are precipitated by Vit D deficiency included increased cardiovascular risk, low immunity & chronic renal failure.
Elevated levels may be seen in patients taking supplements( hence recommended to repeat after 3 months for estimation of accurate levels), Vitamin D intoxication,
sarcoidosis and malignancies containing non regulated 1-alpha hydroxylase in the lesion.
Recommendations
1.To prevent biotin interference the patient should be atleast 8 hours fasting before submitting the sample 2.25(OH)D is the analyte of choice for determination of the
Vitamin D status as it is the major storage & active form of Vitamin D and has longer half-life. 3. Kidney Disease Outcomes Quality Initiatives (KDOQI) and Kidney Disease
Improving Global Outcomes (KDIGO) recommend activated vitamin D testing for CKD patients.
Note-Our Vitamin D assays is standardized to be in alignment with the ID-LC/MS/MS 25(OH)vitamin D Reference Method Procedure (RMP), the reference procedure for the
Vitamin D Standardization Program (VDSP). The VDSP, a collaboration of the National Institutes of Health Office of Dietary Supplements, National Institute of Technology
and Standards, Centers for Disease Control and Ghent University, is an initiative to standardize 25(OH)vitamin D measurement across methods.
Reference:
1.Wallach Interpretation of diagnostic test, 10th edition.
VITAMIN B12(CYANOCOBALAMINE), SERUM-Test description
1.Measures the amount of Vitamin B12/ Cyanocobalamin or Methyl cobalamin in blood.2. Done in Anemic conditions like Megaloblastic anemia, pernicious anemia, dietary
folate deficiencies,3.Workup of neuropathies especially due to diabetes.4.Nerve health and it is monitored in treatment of nerve damage.5.Important vitamin for women of
childbearing age and for older people.
1.Part of water-soluble B complex of vitamins. 2. It is essential in DNA synthesis, hematopoiesis & CNS integrity.3.Source for B12 is dietary foods like milk, yoghurt, eggs,
meat, fortified cereals, bread. 4.Absorption depends on the HCl secreted by the stomach and occurs in intestines. 5. It is part of enterohepatic circulation, hence excreted in
feces(approx. 0.1% per day)
Test interpretation
Higher than normal levels are in patients on Vitamin supplements or patients with COPD, CRF, Diabetes, Liver cell damage, Obesity, Polycythemia.
Decreased levels seen in
Inflammatory bowel disease, Pernicious anemia - genetic deficiency of intrinsic factor - necessary for Vit B12 absorption, Strict vegetarianslead to sub-clinical B12

Page 18 Of 19

Dr. Anurag Bansal Dr.Rashmi Rasi Datta-MD,FIMSA

LAB DIRECTOR DMC-64289
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]
 DIAGNOSTIC REPORT

MC-5716

PATIENT NAME : VIMLESH REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000153714 ACCESSION NO : 0009XH023523 AGE/SEX : 57 Years Female
COFO BEST DIAGNOSTICS SERVICES PATIENT ID : VIMLF644525600 DRAWN : 10/08/2024 12:58:03
SHOP NO. 71/1, GROUND FLOOR, YUSUF SARAI
CLIENT PATIENT ID: RECEIVED : 10/08/2024 16:10:41
MARKET,SOUTH WEST DELHI
ABHA NO : REPORTED : 10/08/2024 19:18:21
SOUTH WEST DELHI 110016
9582311597

Test Report Status Final Results Biological Reference Interval Units

deficiency- high among elderly patients, Malabsorption due to gastrectomy, smoking, pregnancy, multiple myeloma & hemodialysis, Alcohol & drugs like amino salicylic acid,
anticonvulsants, cholestyramine, cimetidine, Hyperthyroidism (High levels of thyroid), Seen in mothers of children with (NTD) Neural tube defects- hence fortification and
supplements are advised in expecting mothers
Recommendations-1.To prevent biotin interference the patient should be atleast 8 hours fasting before submitting the sample. 2. Vit B12 and Folic acid evaluated together
in macrocytic anemias to avoid methyl folate trap. Carmel’s composite criteria for inadequate Vit B12 status: Serum vitamin B12 < 148 pmol/L, or 148–258 pmol/L and
MMA > 0.30µmol/L, or tHcy > 13 nmol/L (females) and >15 nmol/L (males).
Associated Test-Holo-TC: Marker of vitamin B12 status -specificity and sensitivity better than serum vitamin B12, hence recommended in boderline and deficient cases for
confirmation.
References-O-Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010 Mar 2(3):299-316.

**End Of Report**
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient 5. AGILUS Diagnostics confirms that all tests have been
named or identified in the test requisition form. performed or assayed with highest quality standards, clinical
2. All tests are performed and reported as per the safety & technical integrity.
turnaround time stated in the AGILUS Directory of Services. 6. Laboratory results should not be interpreted in isolation;
3. Result delays could occur due to unforeseen it must be correlated with clinical information and be
circumstances such as non-availability of kits / equipment interpreted by registered medical practitioners only to
breakdown / natural calamities / technical downtime or any determine final diagnosis.
other unforeseen event. 7. Test results may vary based on time of collection,
4. A requested test might not be performed if: physiological condition of the patient, current medication or
i. Specimen received is insufficient or inappropriate nutritional and dietary changes. Please consult your doctor
ii. Specimen quality is unsatisfactory or call us for any clarification.
iii. Incorrect specimen type 8. Test results cannot be used for Medico legal purposes.
iv. Discrepancy between identification on specimen 9. In case of queries please call customer care
container label and test requisition form (01149575757 / 9111591115) within 48 hours of the report.
.
Agilus Diagnostics Ltd
Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062

Page 19 Of 19

Dr. Anurag Bansal Dr.Rashmi Rasi Datta-MD,FIMSA

LAB DIRECTOR DMC-64289
Consultant Biochemist & Section
Head
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Reference Lab,2nd Floor, Plot No. 31,Urban Estate Electronic City,Sector-18,
Gurgaon, 122015 ULR No.9000013983963-0009
Haryana, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Global Tel: 91115 91115
Email : [email protected]